It’s a case of so far, so good for Ipsen with its recent acquisition of Albireo, after the main asset in the deal – Bylvay – secured FDA approval for its second rare disea
Ipsen’s Cabometyx should not be used by the NHS for patients with differentiated thyroid cancer who have either not responded to or are ineligible for radioactive iodine t
Could Ipsen’s marathon attempt to get its palovarotene drug candidate for rare disease fibrodysplasia ossificans progressiva (FOP) finally be nearing the finish line in th
Ipsen has announced the three-year follow up results from its CheckMate -9ER study, showing that Cabometyx (cabozantinib) in combination with nivolumab shows durable survi
Ipsen has suffered rather a setback in its marathon effort to bring palovarotene to market for ultra rare disease fibrodysplasia ossificans progressiva (FOP), after EU advisors recommended
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho